CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib.

Blood Neoplasia · 2024 · PMC12082111 · PMID 40454393

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = .09so close (0.05 < p ≤ 0.1)

The halving time from 3 to 6 months for PR-1 was higher than GR but did not reach statistical significance ( P = .09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.